home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 10/20/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn study of leronlimab for COVID-19 passes first safety review

The independent Data Safety Monitoring Committee ((DSMC)) has completed its first interim analysis of a Phase 2b/3 clinical trial evaluating CytoDyn's (CYDY) leronlimab in severe-to-critical COVID-19 patients. The analysis was performed on data from the first 50% (n=195) of participants.The D...
CYDY - CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b/3 COVID-19 Registrational Trial

DSMC recommend s CytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint DSMC also request s another data review when enrollment reache s 29 3 patients (75%) to analyze all data,...

CYDY - * * REVISED TIME * * CytoDyn to Hold Webcast on October 20 to Discuss DSMC's Recommendations from the Interim Analysis of the Phase 2b/3 Clinical Trial for Severe-to-Critical COVID-19 Patients

VANCOUVER, Washington, Oct. 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...

CYDY - CytoDyn to discuss DSMC's review of interim analysis in COVID-19 on October 20

CytoDyn (CYDY) will host an investment community webcast on Tuesday, October 20. Management will discuss the recommendations of the Data Safety Monitoring Committee ((DSMC)) following their review of the interim analysis of the first 195 patients enrolled in the Company’s Pha...
CYDY - CytoDyn to Hold Webcast on October 20 to Discuss DSMC's Recommendations from the Interim Analysis of the Phase 2b/3 Clinical Trial for Severe-to-Critical COVID-19 Patients

VANCOUVER, Washington, Oct. 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...

CYDY - CytoDyn: COVID-19 High Anxiety

CytoDyn's prospects as a potential lead therapeutic for mild-to-moderate COVID-19 are looking much diminished. CytoDyn is facing a key catalyst within days as regards mortality in its severe/critical COVID-19 trial. CytoDyn's rush to assure adequate supplies of leronlimab, a molec...

CYDY - CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines

VANCOUVER, Washington, Oct. 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY ), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
CYDY - CytoDyn to Hold 2020 Virtual Annual Meeting of Stockholders on September 30, 2020

VANCOUVER, Washington, Sept. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY ), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, remin...

CYDY - CytoDyn's Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on 'Therapeutics for COVID-19'

VANCOUVER, Washington, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY ), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, annou...

CYDY - CytoDyn's CEO Dr. Pourhassan and CMO Dr. Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020

VANCOUVER, Washington, Sept. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY ), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, annou...
Previous 10 Next 10